City of Hope Part of Successful International Phase 3 Clinical Trial Evaluating Sotorasib Medication Combination for Patients With Metastatic Colorectal Cancer
October 28, 2023
October 28, 2023
LOS ANGELES, California, Oct. 28 (TNSres) -- City of Hope issued the following news release on Oct. 27, 2023:
An international Phase 3 clinical trial found that metastatic colorectal cancer patients with a rare genetic tumor mutation called KRAS G12C experienced superior progression-free survival rates compared to standard of care when offered a combination treatment of KRAS inhibitor sotorasib and monoclonal antibody panitumumab. City of Hope, one of the largest cancer research and . . .
An international Phase 3 clinical trial found that metastatic colorectal cancer patients with a rare genetic tumor mutation called KRAS G12C experienced superior progression-free survival rates compared to standard of care when offered a combination treatment of KRAS inhibitor sotorasib and monoclonal antibody panitumumab. City of Hope, one of the largest cancer research and . . .